Cette page a été traduite automatiquement et l'exactitude de la traduction n'est pas garantie. Veuillez vous référer au version anglaise pour un texte source.

Responses to Exposure to Low Levels of Concentrated Ambient Particles in Healthy Young Adults (RECAP)

3 septembre 2021 mis à jour par: David Diaz-Sanchez, Environmental Protection Agency (EPA)
Purpose: To determine whether exposure to levels of fine particles that are close to the current standard will cause cardiovascular changes in healthy individuals.

Aperçu de l'étude

Statut

Complété

Les conditions

Intervention / Traitement

Description détaillée

Air pollution is associated with several adverse health outcomes. Specifically, ambient fine particulate matter ≤2.5 μg/m3 (PM2.5) is associated with increased mortality and increased risk for respiratory and cardiovascular disease It has been estimated that worldwide over 3.2 million premature deaths and over 74 million years of healthy life lost were attributable to ambient particulate matter pollution, making it one of the top global health risk factors . Further, an estimated 22% of disability-adjusted life-years for heart disease are attributable to ambient particulate matter pollution. Similarly, it is estimated that air pollution exposure contributed to about 6% (3.7 million) of all deaths in 2012, with 40% of those coming from coronary artery disease (CAD). More than 100 time-series and case-crossover analyses have demonstrated associations of short term PM2.5 exposure with myocardial infarctions (MIs); aggravated asthma and increased risk for hospitalizations and mortality. These studies suggest that the acute health effects of air pollution particularly affect infants and children, older adults, and those with underlying disease, such as diabetes and cardiovascular disease (Pope, 2014). In healthy and younger individuals (<65 year old) these same studies observe associations between air pollution and subclinical biomarkers of inflammation, coagulation and oxidative stress but not for any clinical outcomes. This has led the American Heart Association to state that" Despite theoretical statistical risks ascribed to all individuals, this elevated risk from exposure is not equally distributed within a population. At present-day levels, PM2.5 likely poses an acute threat principally to susceptible people, even if seemingly healthy, such as the elderly and those with (unrecognized) existing coronary artery or structural heart disease."

Controlled human exposure studies are a critical component of the health risk assessment for ozone because of their ability to establish exposure-response relationships at low doses and have therefore weighed heavily in deliberations when the U.S. EPA has considered the National Ambient Air Quality Standard (NAAQS). In contrast, for PM2.5, controlled exposure studies have been used primarily to demonstrate biological plausibility. that is the potential for particulate matter to exert extra-pulmonary effects. These studies have shown that healthy volunteers primarily exhibit mild pulmonary inflammation, decreases in heart rate variability and changes in blood factors associated with blood coagulation following exposure to concentrated air particles (CAPs), most show no change in lung function and none result in cardiac arrhythmia. Nearly all these studies have been conducted at realistic but high levels of PM2.5 (typically above 100 µg/m3). Currently the EPA 24-hour fine particle standard is 35µg/m3, a value based predominantly on epidemiologic studies. While epidemiologic studies suggest that similar effects can occur at lower levels, it is difficult for these association studies to conclusively demonstrate because of the problems in disassociating the effects of PM2.5 from other pollutants and confounders. Only a controlled human exposure study can determine directly whether PM2.5 can alter cardiovascular endpoints at lower concentrations. Four hours represents a typical exposure duration to particulate matter during the course of the day.

Type d'étude

Interventionnel

Inscription (Réel)

20

Phase

  • N'est pas applicable

Contacts et emplacements

Cette section fournit les coordonnées de ceux qui mènent l'étude et des informations sur le lieu où cette étude est menée.

Lieux d'étude

  • États-Unis
    • North Carolina
      • Chapel Hill, North Carolina, États-Unis, 27514
        • U.S. EPA Human Studies Facility

Critères de participation

Les chercheurs recherchent des personnes qui correspondent à une certaine description, appelée critères d'éligibilité. Certains exemples de ces critères sont l'état de santé général d'une personne ou des traitements antérieurs.

Critère d'éligibilité

Âges éligibles pour étudier

18 ans à 35 ans (Adulte)

Accepte les volontaires sains

Oui

Sexes éligibles pour l'étude

Tout

La description

Inclusion Criteria:

  • Healthy individuals ages 18-35 years of age
  • Physical conditioning allowing intermittent, moderate exercise for four hours. Ability to complete the exposure exercise regimen without reaching 80% of predicted maximal heart rate. Predicted maximal heart rate will be calculated using the equation (described by Tanaka et al.: [2001] J. Am. Coll. Cardiol.): [208bpm-((0.7) x (age in years))]
  • Normal baseline 12-lead EKG .

  • Normal lung function

    1. Forced vital capacity (FVC) ≥ 80% of that predicted for gender, ethnicity, age and height (according to NHANESIII guidelines).
    2. Forced expiratory volume in one second (FEV1) ≥ 80%of that predicted for gender,ethnicity, age and height
    3. FEV1) /FVC ratio≥ 80% of predicted values.
  • Oxygen saturation ≥ 96% on room air.

Exclusion Criteria:

  • Individuals with a history of acute or chronic cardiovascular disease, chronic respiratory disease, diabetes, rheumatologic diseases, or immunodeficiency state.
  • Individuals with a CVD risk score greater than 10% using the ACC/AHA ASCVD risk calculator.
  • Individuals with clinically diagnosed asthma.
  • Individuals who are allergic to chemical vapors or gases.
  • Females who are pregnant, attempting to become pregnant, or breastfeeding.
  • Individuals that are unable or unwilling to stop for at least two weeks prior to the study taking medications, vitamins or supplements that the investigators believe may impact the results of the study. Those not specifically mentioned here may be reviewed by the investigators prior to an individual's inclusion in the study.
  • Individuals who smoke/vape more than 2 times per month and have smoked/vaped within 4 weeks prior to all study visits.
  • Individuals living with a smoker who smokes inside the house.
  • Individuals with a body mass index (BMI) >35 or <18. Body mass index is calculated by dividing the weight in kilograms by the square of the height in meters.
  • Individuals with occupational exposures to high levels of vapors, dust, gases, or fumes on an on-going basis.
  • Individuals with uncontrolled hypertension (≥150 systolic or ≥90 diastolic).
  • Individuals that do not understand or speak English.
  • Individuals that are unable to perform the exercise required for the study.
  • Individuals that are taking beta blocker medications.
  • Individuals with a history of skin allergies to adhesives used in securing EKG electrodes.
  • Individuals with unspecified diseases, conditions, or medications that might influence the responses to the exposures, as judged by the medical staff.
  • Individuals that are unwilling or unable to stop taking over-the-counter pain medications such as aspirin, ibuprofen (Advil, Motrin), naproxen (Aleve), or other non-steroidal anti-inflammatory ("NSAID") medications for 48 hours prior to the exposures and post-exposure visits.
  • Individuals that are taking systemic steroids or beta-blocker medications.
  • Individuals with a hemoglobin A1c (HbA1c) level > 6.4%.

Temporary Exclusion Criteria:

  • Individuals suffering from acute respiratory illness within four weeks prior to any of the study exposure series.
  • Individuals that have been exposed to smoke and fumes within 24 hours of any study visit.
  • Individuals that have engaged in strenuous exercise within 24 hours of any study visit.
  • Individuals that have been exposed to ozone-based home air purifiers within 24 hours of any study visit.
  • Individuals unable to avoid drinking alcohol for 24 hours prior to all study visits.
  • Individual unable to avoid caffeine for 12 hours prior to all study visits and during each study visit.
  • Individuals that have been exposed to unvented household combustion sources (gas stoves, lit fireplaces, oil/kerosene heaters) within 48 hours of any study visit.
  • Individuals that have been exposed to or have consumed any agent or have undertaken any activity within 24 hours of any study visit that the investigators believe may compromise the results of the study.

Plan d'étude

Cette section fournit des détails sur le plan d'étude, y compris la façon dont l'étude est conçue et ce que l'étude mesure.

Comment l'étude est-elle conçue ?

Détails de conception

  • Objectif principal: Science basique
  • Répartition: Randomisé
  • Modèle interventionnel: Affectation croisée
  • Masquage: Double

Armes et Interventions

Groupe de participants / Bras
Intervention / Traitement
Comparateur factice: L'air pur
L'exposition à l'air pur sera effectuée dans une chambre d'exposition à l'EPA Human Studies Facility sur le campus de l'UNC.
Autre: Clean Air
Each subject will be exposed to clean air for 4 hours. Subjects will exercise on a bike or treadmill. Each exercise session will consist of a 15 minute exercise interval at a level of up to 25 L/min/m2BSA followed by a 15 minute rest period.
Comparateur actif: Concentrated PM2.5
Exposure to PM2.5 will be conducted in an exposure chamber at the EPA Human Studies Facility on the UNC campus.
Autre: PM2.5
Each subject will be exposed up to 35-50 μg/m3 PM2.5 for 4 hours. Subjects will exercise on a bike or treadmill. Each exercise session will consist of a 15 minute exercise interval at a level of up to 25 L/min/m2BSA followed by a 15 minute rest period.

Que mesure l'étude ?

Principaux critères de jugement

Mesure des résultats
Description de la mesure
Délai
Changes in heart rate variability
Délai: Pre exposure to 24hours post exposure
10 minute electrocardiogram recording (measured by Holter ECG) in which the
Pre exposure to 24hours post exposure

Mesures de résultats secondaires

Mesure des résultats
Description de la mesure
Délai
Volume expiré forcé dans la première seconde (FEV1)
Délai: Pré exposition à 24 heures après exposition
Le volume expiré forcé dans la première seconde (FEV1) est déterminé par spirométrie effectuée sur un spiromètre à joint sec interfacé à un ordinateur.
Pré exposition à 24 heures après exposition
Capacité vitale forcée
Délai: Pré exposition à 24 heures après exposition
La capacité vitale forcée (CVF) est déterminée par spirométrie effectuée sur un spiromètre à joint sec interfacé à un ordinateur.
Pré exposition à 24 heures après exposition
Index of inflammatory markers
Délai: Pre exposure to 24hours post exposure
Index of inflammatory markers is the mean % changes in a basket of factors related to systemic inflammation (IL-6, IL-8, TNF-a, IL-b, CRP) in the blood following exposure to PM2.5 vs. clean air.
Pre exposure to 24hours post exposure

Collaborateurs et enquêteurs

C'est ici que vous trouverez les personnes et les organisations impliquées dans cette étude.

Parrainer

Environmental Protection Agency (EPA)

Publications et liens utiles

La personne responsable de la saisie des informations sur l'étude fournit volontairement ces publications. Il peut s'agir de tout ce qui concerne l'étude.

Publications générales

Liens utiles

Dates d'enregistrement des études

Ces dates suivent la progression des dossiers d'étude et des soumissions de résultats sommaires à ClinicalTrials.gov. Les dossiers d'étude et les résultats rapportés sont examinés par la Bibliothèque nationale de médecine (NLM) pour s'assurer qu'ils répondent à des normes de contrôle de qualité spécifiques avant d'être publiés sur le site Web public.

Dates principales de l'étude

Début de l'étude (Réel)

16 janvier 2017

Achèvement primaire (Réel)

20 janvier 2019

Achèvement de l'étude (Réel)

30 juillet 2020

Dates d'inscription aux études

Première soumission

25 juillet 2017

Première soumission répondant aux critères de contrôle qualité

25 juillet 2017

Première publication (Réel)

27 juillet 2017

Mises à jour des dossiers d'étude

Dernière mise à jour publiée (Réel)

5 septembre 2021

Dernière mise à jour soumise répondant aux critères de contrôle qualité

3 septembre 2021

Dernière vérification

1 septembre 2021

Plus d'information

Termes liés à cette étude

Mots clés

Autres numéros d'identification d'étude

  • 16-1548

Plan pour les données individuelles des participants (IPD)

Prévoyez-vous de partager les données individuelles des participants (DPI) ?

NON

Description du régime IPD

IPD will not be shared.

Informations sur les médicaments et les dispositifs, documents d'étude

Étudie un produit pharmaceutique réglementé par la FDA américaine

Non

Étudie un produit d'appareil réglementé par la FDA américaine

Non

Ces informations ont été extraites directement du site Web clinicaltrials.gov sans aucune modification. Si vous avez des demandes de modification, de suppression ou de mise à jour des détails de votre étude, veuillez contacter register@clinicaltrials.gov. Dès qu'un changement est mis en œuvre sur clinicaltrials.gov, il sera également mis à jour automatiquement sur notre site Web .

Essais cliniques sur Exposition à la pollution

Essais cliniques sur Clean Air

Rechercher des essais similaires

Sponsors et collaborateurs

Les conditions médicales

Interventions en matière de drogue

CROs by country

CROs in Tanzania

Conditions

Maladies rares

Interventions en matière de drogue

Compléments alimentaires

Commanditaire / collaborateurs

Emplacements

S'abonner